Physician profile
James B Hammock
NPI 1700382462
$790.81
in general payments reported to CMS, 2019-2025
10 companies · $572 in 2025
The $572 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $219 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $231.90 | 2024-2025 | |
| Pfizer INC. | $151.44 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $122.51 | 2024-2025 | Camzyos, Eliquis |
| Amgen INC. | $98.09 | 2024-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.34 | 2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $29.54 | 2025 | Farxiga |
| Medtronic, INC. | $18.47 | 2025 | Venaseal |
| Lantheus Medical Imaging, INC. | $17.71 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $17.68 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.13 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hammock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.